Loading
A phase 2 trial of PM8002, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by BioNTech SE, now recruiting.
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment is a phase 2 interventional study registered as NCT06841055 by BioNTech SE, with 60 participants planned, started 2025-03-03 and due to reach its primary completion in 2028-10. Interventions recorded: Pumitamig, Docetaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/